Advertisement

  • Loading metrics

Open Access

Peer-reviewed

Research Article

A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy

  • Andie I. Lun ,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Software, Writing – original draft

    andie.lun1@nhs.net

    Affiliations Department of Infection, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital, Brighton, United Kingdom, Department of Global Health and Infection, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, United Kingdom, The London School of Hygiene and Tropical Medicine, London, United Kingdom

    ⨯
  • Barbara de Barros,

    Roles Methodology, Writing – review & editing

    Affiliation The London School of Hygiene and Tropical Medicine, London, United Kingdom

    ⨯
  • Stephen L. Walker

    Roles Conceptualization, Methodology, Supervision, Visualization, Writing – review & editing

    Affiliations The London School of Hygiene and Tropical Medicine, London, United Kingdom, Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom, Department of Dermatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    ⨯
?

This is an uncorrected proof.

Abstract

Background

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae) and Mycobacterium lepromatosis (M. lepromatosis), primarily affecting the skin and peripheral nervous system. Leprosy is complicated by immune-mediated reactions which are risk factors for nerve damage and disability. Systemic corticosteroids are the mainstay of therapy; however, prolonged use in chronic or recurrent reactions carries significant risks but the evidence on the short- and long-term adverse effects of corticosteroids in leprosy is limited. We conducted a systematic review to evaluate corticosteroid-associated adverse effects in leprosy affected individuals.

Methodology

Eight electronic databases were searched (including PubMed, Embase and LILACS) without language or year restriction for studies reporting adverse effects associated with systemic corticosteroid use in individuals with leprosy. Eligible studies included randomised controlled trials, observational studies, case series and case reports. Data variability was assessed using Stata software.

Main findings

A total of 111 studies were included; of which 22 were randomised controlled trials. Due to heterogeneity, findings were synthesised narratively. The most frequently reported adverse effects were metabolic complications, with approximately one-third of individuals developing corticosteroid-induced lipodystrophy. Infections were the second most common adverse effect (15.5%), followed by gastritis (12.6%). Infections accounted for three-quarters of corticosteroid-associated mortality, predominantly due to tuberculosis, with 88.2% of corticosteroid-associated mortalities occurring in individuals with erythema nodosum leprosum (ENL). There was an association between ENL and the development of cataract and osteoporosis, with 69.7% of cataract cases and 84.4% of osteoporosis cases occurring among individuals with ENL.

Conclusion

This systematic review illustrates the range and severity of adverse effects affecting individuals with leprosy who received systemic corticosteroids. Although this review is limited by study heterogeneity, publication bias, and the scarcity of long-term data, it highlights the need for corticosteroid stewardship, structured pharmacovigilance and further research for safer therapeutic alternatives to corticosteroids for leprosy reactions.

Author summary

Leprosy is a neglected tropical disease that causes stigmatising disability and is associated with significant reduction in quality of life. The infectious organism and the body’s immune response to it causes nerve damage often with severe, painful episodes called leprosy reactions. Leprosy reactions are the major risk factor for disability and are treated with corticosteroids. Corticosteroids are used in many inflammatory conditions with well recognised adverse effects, but data on these adverse effects in individuals with leprosy are limited.

We conducted a systematic review to characterise the nature and frequency of the adverse effects associated with corticosteroid use in people with leprosy. Our review found that adverse effects affected many organ systems and some were particularly frequent and severe in individuals who required prolonged treatment. Our results highlight the importance of monitoring patients with leprosy who are prescribed corticosteroids and reveal significant gaps within existing literature to inform future research. Strengthening pharmacovigilance of corticosteroid use and monitoring practices could help improve care.

Citation: Lun AI, de Barros B, Walker SL (2026) A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy. PLoS Negl Trop Dis 20(3): e0014152. https://doi.org/10.1371/journal.pntd.0014152

Editor: Anil Fastenau, Marie Adelaide Leprosy Centre Pakistan, PAKISTAN

Received: January 5, 2026; Accepted: March 16, 2026; Published: March 26, 2026

Copyright: © 2026 Lun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The dataset supporting this review is available in the Zenodo repository at https://doi.org/10.5281/zenodo.19004521.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Leprosy is a neglected tropical disease caused by Mycobacterium leprae (M. leprae) and Mycobacterium lepromatosis (M. lepromatosis) [1]. They are obligate intracellular, non-motile, acid-fast bacilli that have tropism for dermal macrophages, neuronal dendritic and Schwann cells [1,2]. A total of 172,717 new cases from 129 countries were reported to the World Health Organization (WHO) in 2024, among which 5.3% reported severe impairment with Grade 2 disability at diagnosis [3].

The clinical spectrum of leprosy is influenced by the affected individual’s immune response to the infection, specifically one’s cell-mediated immunity involving T cells and macrophages [4]. The Ridley and Jopling classification uses clinico-pathological correlation to classify leprosy into tuberculoid (TT) leprosy, borderline tuberculoid (BT), borderline borderline (BB), borderline lepromatous (BL) and lepromatous leprosy (LL) [5]. Individuals with TT leprosy have high cell-mediated activity, no identifiable bacteria in tissues and few skin lesions whereas people with LL have low cell-mediated activity, large numbers of bacteria and many skin lesions and/or widespread skin infiltration [4].

Leprosy reactions are immune-mediated responses to M. leprae/lepromatosis infection. A large proportion of individuals affected by leprosy will experience leprosy reactions. In a Brazilian randomised controlled trial (RCT) of anti-microbial treatment for WHO multibacillary leprosy, over 60% of participants experienced a leprosy reaction during six years of observation [6].

Leprosy reactions are the main risk factor for disability. The odds of disability are increased up to 12 times in individuals with LL [2,7]. Disability is associated with physical, psychological, economic and social impairments with reduced quality of life [8]. Leprosy reactions are categorized as Type 1 reactions (T1Rs), also known as reversal reactions, and erythema nodosum leprosum (ENL) or Type 2 reactions [9]. Reactions may occur before, during or after successful completion of antimicrobial therapy [2].

T1R may affect individuals with any type of leprosy and occur in 20–40% of individuals with borderline forms of leprosy [10–12]. T1R may present with erythematous skin lesions, oedema, neuritis (characterized by nerve tenderness) and nerve function impairment (NFI) [13,14]. NFI may be permanent if treatment is delayed, and 8–20% of individuals with NFI do not improve despite treatment [15,16]. ENL is a multisystem inflammatory disorder affecting individuals with BL leprosy or LL [17,18]. A single acute episode of ENL is rare, and most individuals experience recurrent or chronic episodes over many years [19,20]. A retrospective study of patients with ENL reviewed at The Hospital for Tropical Diseases in London found a median disease duration of 5 years [21]. In addition, a large retrospective cohort study conducted in India reported 80% of patients with ENL became dependent on corticosteroids [20]. Although ENL typically occurs during anti-microbial treatment, reactions may also occur up to eight years after treatment completion, further illustrating its unpredictable and chronic nature [22,23]. The clinical and public health burden of ENL is substantial, with a study conducted in Ethiopia reporting a 6.4 times higher odds of mortality in people with ENL compared to those with T1R [24].

Corticosteroids have been used to treat leprosy reactions and NFI since 1952 and have broad anti-inflammatory and immunosuppressive effects [25,26]. The WHO recommend oral corticosteroids for T1R and neuritis unresponsive to simple analgesia, starting with 0.5-1mg/kg/day tapering over 20 weeks [27]. Corticosteroids are recommended as the first line treatment for ENL using initial doses of prednisolone 30–40 mg/day, whereas recurrent or chronic T2R is best controlled with thalidomide at 100–400 mg/day [27]. Thalidomide is effective in ENL but is unavailable in many leprosy endemic countries due to its teratogenicity [28,29].

Corticosteroids are associated with a wide variety of adverse effects when used to treat inflammatory conditions. Adverse effects include infections, gastrointestinal symptoms, osteoporosis, fractures, glucocorticoid-induced Cushing syndrome (GICS), glucocorticoid-induced diabetes mellitus (GIDM), as well as cardiovascular disease and psychiatric complications [30–35]. GICS is characterised by corticosteroid-induced lipodystrophy, weight gain and acneiform eruption [36,37]. Adverse effects from corticosteroids are closely associated with dose and duration, with effects such as osteoporosis and GIDM arising early in treatment compared to cataracts and fractures which occur later [38]. Evidence from a meta-analysis found higher cumulative corticosteroid exposure to be associated with an increased risk of fracture [39], and a case-control study of participants with systemic lupus erythematosus found 12% increased odds of infection with each 1mg/day increase in prednisolone dose [40].

The frequency of leprosy reactions and lack of available alternatives to corticosteroids means many individuals are prescribed corticosteroids at high doses and for prolonged periods, exposing them to the risk of corticosteroid-associated adverse effects [20,24]. We wished to conduct a systematic review to evaluate the nature and frequency of AEs associated with corticosteroid in people affected by leprosy.

Methods

The study was registered prospectively on PROSPERO on 27th June 2025 (registration number CRD420251059485). The protocol is available at https://www.crd.york.ac.uk/PROSPERO/view/CRD420251059485.

This systematic review was conducted and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines (S1 File).

Search strategy

A comprehensive search was performed on 28th May 2025, across eight major databases: PUBMED, MEDLINE, EMBASE (via OVID), The Cochrane Library (CENTRAL), CINAHL, LILACS, Global Index Medicus, and SCOPUS. The strategy combined controlled vocabulary terms (e.g., Leprosy, Steroids, Drug-related Side Effects and Adverse Reactions) with free-text keywords for corticosteroids, adverse outcomes, and leprosy reactions (including erythema nodosum leprosum, reversal reactions, Type 1 and Type 2 reaction). Boolean and proximity operators were used (S1 Text). A filter from Canada’s Drug Agency for adverse effects was consulted to supplement the search strategy [41].

Inclusion and exclusion criteria

RCTs, prospective and retrospective cohort studies, case-control studies, case series, and case reports that met pre-specified inclusion criteria were included. Non-human studies and in-vitro investigations were excluded. No language or temporal restrictions were imposed; articles not in English were translated using Google Translate. Letters to the editor, editorials, and commentaries were excluded unless they reported original outcome data. Studies were eligible if they included individuals with leprosy, diagnosed by WHO 2018 criteria or laboratory confirmation [42], who received systemic corticosteroids for nerve function impairment or leprosy reactions. Comparators included placebo, other medications, or different corticosteroids regimens. Outcomes of interest were corticosteroid-related adverse effects.

Backward citation searching was conducted by reviewing the reference lists of all included studies, and authors were contacted for further information if required. Conference proceedings were included as grey literature. The study selection process was conducted by one reviewer, with any uncertainties resolved through discussion with a second reviewer and, if necessary, adjudicated by a third reviewer.

Data extraction

Data from eligible studies were extracted using a standardized Microsoft Excel spreadsheet. The extracted data included study design, population characteristics, indication, intervention details (type, dosage, comparator(s), placebo, alternative medicines, or dosage variations), and all reported AEs associated with systemic corticosteroid therapy. When necessary, study authors were contacted to clarify or provide missing information to ensure data completeness.

The primary outcome of interest was AEs associated with corticosteroid use for the management of leprosy reactions. ‘Adverse effect’ was defined according to the pharmacovigilance body of WHO, as “a negative or harmful patient outcome that seems to be associated with treatment, including there being no effect at all” [43].

Corticosteroid exposure was categorized as either ‘corticosteroid-naïve,’ defined as no prior exposure to corticosteroid therapy, or ‘corticosteroid-experienced,’ defined as previous exposure or established tolerance to corticosteroid therapy.

Risk of bias assessment

All included studies were critically appraised. Version 2 of the Cochrane risk-of-bias tool (RoB 2) was used to critically appraise RCTs [44]; the Newcastle Ottawa Scale was used to assess prospective and retrospective cohort studies [45]; the Joanna Briggs Institute critical appraisal tool was used to assess case series and case reports [46].

Statistical analysis

Statistical analyses were performed using StataCorp (version 18). The extent of heterogeneity among included studies was determined by calculating the I² statistic and conducting tests of homogeneity. In instances where there were zero numerator events in outcome data, reciprocal correction was applied following recommendations in the Cochrane Handbook [47]. Risk ratio (RR) and 95% confidence interval (CI) were calculated where possible when analysing data from narrative synthesis. Where only total AEs were reported (allowing for multiple events per individual), the event risk per person was used to avoid violating assumptions of independence [48].

Ethical approval

This study was undertaken as part of the requirements of a master’s degree at the London School of Hygiene & Tropical Medicine. Ethical approval for this study was requested through submission of a combined academic, risk assessment and ethics form, which was reviewed by the Research Governance & Integrity Office as not requiring ethical approval from the ethics committee.

Results

Overview of all included studies

A total of 111 studies from 19 countries published between 1955 and 2025 were included. Most were from India (n = 50) and Brazil (n = 15), which reflects the current global distribution of leprosy. The review identified 22 RCTs, 14 prospective studies, 5 retrospective studies, 56 case reports and 14 case series. Eight information requests were sent to authors, or to libraries when author contact details were unavailable; none received a response. Two supplementary publications were used to extract AE data for the TRIPOD and TENLEP trials [49,50], as some AEs were reported separately from the primary trial publications.

Prednisolone was the most frequently used corticosteroid, with cortisone appearing in earlier studies. Participants were aged 3–80 years old though mostly adults; 76.1% were male and 62.1% of studies focused on ENL. The results of study identification and screening are presented in a flow diagram as shown in Fig 1 [51].

thumbnail
Download:
Fig 1. XXX.

https://doi.org/10.1371/journal.pntd.0014152.g001

Randomised controlled trials

A total of 22 RCTs were categorized according to reaction type: prophylaxis (n = 2), T1R and NFI (n = 11), and ENL (n = 9). The RCTs compared corticosteroid with placebo, corticosteroid with non-corticosteroid agents and lower corticosteroid doses with higher ones. Trials with identical corticosteroid regimens or unquantifiable data were excluded from meta-analysis.

Randomised controlled trials of Type 1 reactions and nerve function impairment

Table 1 summarises the characteristics of the included RCTs on T1R and NFI. All were double blinded except one. The TRIPOD trials tested prevention (TRIPOD 1), early treatment (TRIPOD 2) and late treatment (TRIPOD 3) of NFI in leprosy [15,51,52]. The TENLEP trials compared prednisolone durations for recent NFI (TENLEP clinical) and examined early treatment of subclinical neuropathy (TENLEP subclinical) [53]. Of 1,920 participants, 86% received oral prednisolone and one study used pulsed intravenous methylprednisolone [54]. The corticosteroid treatment duration ranged from 16 to 20 weeks, with follow-up of up to 19.5 months. No trial was at high risk of bias. The details of risk of bias of RCTs can be found in S1 Table.

thumbnail
Download:
Table 1. Summary of randomised controlled trials reporting corticosteroid-associated adverse effects in Type 1 reaction & nerve function impairment.

https://doi.org/10.1371/journal.pntd.0014152.t001

Most participants were male (89.2%), though data other than corticosteroid-associated AEs for the TENLEP subclinical trial were not reported [50]. Placebo-controlled and dose-comparison trials showed no difference in overall AE risk with prednisolone.

Three RCTs directly compared oral prednisolone with placebo and showed negligible heterogeneity (I² < 0.001; Q = 1.53, p = 0.470) [15,50,52]. Data extraction was limited by pooled reporting and incomplete data [15,50,52].

Randomised controlled trials of erythema nodosum leprosum

Between 1969 and 2025, 11 RCTs investigated and reported adverse effects associated with corticosteroid therapy for ENL (Table 2). Prednisolone was the most frequently used, given at doses between 15 and 60mg daily for 4 weeks to 6 months; betamethasone was used in one study [58]. Three trials were open-label and two reported the occurrence of AEs but not their frequency [58,59]. Overall, 288 of 468 (61.5%) participants received corticosteroids, most were male (82.7%), and the mean follow-up was 6.5 months.

thumbnail
Download:
Table 2. Summary of randomised controlled trials reporting corticosteroids-associated adverse effects in Erythema Nodosum Leprosum.

https://doi.org/10.1371/journal.pntd.0014152.t002

Five RCTs compared prednisolone with non-corticosteroid medications, but one was excluded from meta-analysis due to insufficient AE data [60–64]. Analysis of the remaining four showed moderate heterogeneity (I² = 47.5%, Q = 4.12, p = 0.128). Given the small number of trials, modest sample sizes and only one study with low risk of bias, meta-analysis was deemed inappropriate (S1 Table). The risk ratio of the four RCTs ranged from 0.02 - 2.32, with no studies demonstrating a significant increase in risk of AEs corticosteroids compared with non-corticosteroid regimens (Table 2).

Randomised controlled trials of corticosteroids for leprosy reaction prophylaxis

Two double-blind RCTs assessed corticosteroids for preventing leprosy reactions and NFI (Table 3). Doull et al compared four interventions (placebo, dexamethasone 1.5mg/day, methandrostelone and mefenamic acid) [65]. There was no significant difference in the risk of AEs between the placebo and corticosteroid arms (RR 2.76, 95% CI 0.11-66.90; p = 0.530), although there is potential bias from unclear randomisation and missing outcome data (S1 Table). Smith et al 2004 (TRIPOD 1), assessed oral prednisolone 20mg/day for 12 weeks versus placebo [51]. The study reported a 1.68 times higher risk in overall AEs in the corticosteroid arm compared with placebo (95% CI 1.23-2.36; p = 0.002) [51]. The overall risk of bias was low, supported by a large sample size and clear methods for randomisation and outcome assessment.

thumbnail
Download:
Table 3. Summary of leprosy reaction or nerve function impairment prophylaxis trials reporting corticosteroid-associated adverse effects.

https://doi.org/10.1371/journal.pntd.0014152.t003

Prospective cohort studies

Fourteen prospective cohort studies were included and had a mean follow-up of 29.6 months (S3 Table) [70–83]. Of the fourteen studies, ten included participants receiving corticosteroids for T1R, NFI or ENL, although three of these did not quantify AEs. Four of the fourteen studies assessed only individuals with ENL [77–79,84]. Two studies included pre-defined, non-randomised comparison groups [79,82], while the others were single-group prospective cohorts, generally with moderate risk of bias (S2 Table). Prednisolone was used in all but one study which used betamethasone, and prednisolone doses ranged from 25-60 mg/day for 3 weeks to 14 months [70]. Overall, studies including participants with T1R, NFI or ENL reported AE rates ranging from 1.0 to 213.3 per 100 patients, while studies restricted to ENL alone reported rates ranging from 16.7 to 101.2 per 100 patients (S3 Table).

Retrospective studies

Five retrospective studies were included (S4 Table) [21,24,85–87]. Four of which studied individuals with ENL, whereas Siagan et al. included individuals with T1R or ENL [85]. Among included individuals, 68.7% were male, and concomitant therapies included thalidomide, clofazimine, azathioprine and chloroquine; two studies also involved methotrexate and ciclosporin [24]. Most studies were of moderate risk of bias due to a lack of a comparator arm (S2 Table).

Case series and case reports.

A total of 13 case series and 58 case reports were included, with 84.6% of case series involving individuals with ENL (S5 Table). The case reports described 61 patients, predominantly male (78.7%); 81% had prior corticosteroid exposure and 86.7% had ENL. The mean treatment duration was 13 months with a mean follow-up of 16 months. Infection was the most frequently reported AE, and two-thirds of corticosteroid-related deaths (66.7%) were reported in case reports, all in individuals with ENL.

Adverse effects associated with corticosteroids

Mortality.

Seventeen corticosteroid-associated deaths were identified (Table 4). Infections accounted for 76.5% of cases, including 23.1% due to Mycobacterium tuberculosis. Two deaths resulted from septic shock secondary to Strongyloides stercoralis hyperinfection syndrome [88,89]. All deaths reported were in individuals with chronic, severe ENL, except two with undocumented reaction status. Two individuals had been self-administering corticosteroids unsupervised for >18 months [80,90].

thumbnail
Download:
Table 4. Table detailing reported cases of mortality associated with corticosteroid use.

https://doi.org/10.1371/journal.pntd.0014152.t004

Metabolic effects were the most frequently reported followed by infection. Glucocorticoid-induced Cushing syndrome (GICS) occurred at a rate of 65.1 per 100 patients: 32.2% of individuals at risk developed facial corticosteroid-induced lipodystrophy (CIL), 16.8% had acneiform eruptions and 10.5% developed weight gain. 15.3% developed an infection, among those 63.3% were fungal.

Metabolic and endocrine adverse effects

Glucocorticoid-induced cushing syndrome.

GICS was the most frequently reported AE. In RCTs of T1R and NFI, 26.8% of participants developed corticosteroid-induced lipodystrophy (CIL) and 25.1% acneiform eruption (Table 5). Placebo-controlled trials suggested increased risk of CIL and corticosteroid-related acneiform eruptions [50,51]. Smith et al reported a 9.31 times higher risk of developing acneiform eruptions in participants on corticosteroid therapy compared to placebo (RR = 9.31, 95% CI 1.19-73.1; p = 0.009), and the TENLEP subclinical trial found a 1.82 (95% CI 1.22-2.45; p = 0.016) and 1.73 (95% CI 1.29-22.37; p < 0.001) times increase in acne and CIL respectively among those on corticosteroids [50,51]. No dose-response association was shown in dosage-comparison trials [53,54].

thumbnail
Download:
Table 5. Adverse effects reported in randomised controlled trials for T1R & NFI.

https://doi.org/10.1371/journal.pntd.0014152.t005

In ENL, 13.5% developed acneiform eruptions, with up to 41.7% of participants developing CIL with 30mg prednisolone tapered over 8 weeks in an RCT [60] (Table 6). GICS AEs were reported only in individuals receiving corticosteroid. Lambert et al. reported higher risk of acne with 60mg prednisolone daily compared to prednisolone 40mg daily and ciclosporin (RR 3.61, 95% CI 0.92-14.1; p = 0.027) [66]. A mean of 61.3% of treated individuals developed CIL across six prospective cohorts, with onset typically within weeks and resolution after corticosteroid cessation. All individuals with GICS reported in case series had ENL. Despite the high prevalence of GICS across all study designs, no withdrawals from randomised controlled trials were reported, though visible changes can cause considerable distress [72].

thumbnail
Download:
Table 6. Adverse effects reported in randomised controlled trials for erythema nodosum leprosum.

https://doi.org/10.1371/journal.pntd.0014152.t006

Glucocorticoid-induced diabetes mellitus (GIDM)

In RCTs, GIDM occurred in 3.9% of participants with ENL compared to 2.2% in T1R (Table 5–6). No RCT showed a significant difference in prevalence of GIDM between individuals who received corticosteroid compared with those who received placebo. This may be due to small sample sizes and event rarity. Higher corticosteroid doses were not consistently associated with increased risk, and two small ENL RCTs reported GIDM, with cases managed using oral hypoglycaemic agents [16,53,63,64]. 45.4% of all RCTs did not report any monitoring of symptoms or signs of GIDM, and diagnostic methods, when reported, included urinary glucose, random plasma glucose and glycosylated haemoglobin levels (HbA1C). The median duration of follow-up in RCTs was 8.5 months.

Five prospective cohorts reported GIDM in 2.7-6.1% of participants, mostly within 3 months of initiation (Table 7). Two studies noted symptom resolution after cessation, and notably, Papang et al. found higher cumulative corticosteroid exposure strongly predicted GIDM [72,73,75].

thumbnail
Download:
Table 7. Adverse effects reported in prospective cohort studies.

https://doi.org/10.1371/journal.pntd.0014152.t007

GIDM reported in retrospective studies occurred in 3.0–13.4% of individuals (Table 8). Siagian et al. found that treatment greater than 12 weeks doubled the risk of developing AEs, though not specifically GIDM [85]. Severe cases of GIDM were rare but included two fatalities due to diabetic ketoacidosis [54,93].

thumbnail
Download:
Table 8. Adverse effects reported in retrospective cohort studies.

https://doi.org/10.1371/journal.pntd.0014152.t008

71% of GIDM occurred in T2R patients in case reports and case series. Two deaths were linked to prolonged (~18 months) corticosteroid therapy caused by infection in individuals with GIDM [85,86].

Dyslipidaemia

Negera et al. observed elevated low-density lipoprotein and high-density lipoprotein in T2R patients before and after corticosteroid (p = 0.0014), suggesting the possibility of dyslipidaemia associated with corticosteroid exposure, though confounded by the use of multi-drug therapy and the inflammation associated with ENL itself [79].

Hypothalamic-pituitary-adrenal (HPA) axis suppression

HPA axis suppression was reported in eight patients in three case reports, two case series, and a retrospective study. The diagnosis was made by conducting short Synacthen tests and morning cortisol levels [94,95]. Overall, 75% of individuals were on high-dose oral prednisolone (40–60 mg daily) and onset ranged from 5 months to 2 years form corticosteroid initiation [85]. One report described delayed growth and puberty in a 13-year-old child after 11 months of prednisolone therapy [85].

Electrolyte disturbance

Hypokalaemia was reported in one retrospective cohort study and in one case report [85,96]. Siagian et al. reported cases 1–3 years after starting corticosteroids, and exclusively in individuals treated for longer than 12 weeks [85]. One case of hypokalaemia may have been compounded by vomiting and chronic diarrhoea due to strongyloidiasis [96].

Infection adverse effects

Infection was the second most frequently reported corticosteroid-related AE, affecting 16.8% of individuals experiencing AEs. Fungal infections were the most frequently reported infection (63.3%), followed by tuberculosis (48% of bacterial infections) and strongyloidiasis, which, although less frequently reported, constituted nearly half of parasitic infections. A prospective study reported 1.66 times higher risk of any infection in participants with ENL compared to those with T1R (95% CI 1.30- 2.19; p < 0.001) [72]. Most infections occurred in corticosteroid-experienced individuals. Among individuals with an infection, 16.5% had glucocorticoid-induced diabetes. A more detailed risk factor assessment of infections was limited due to a lack of data on affected participants’ co-morbidities.

Fungal infection

Dermatophyte infection was common, reported in up to 51.5% of participants with ENL in RCTs and comprised 82% of infections in prospective cohort studies with median follow up of 11 years. These cases were generally mild and responsive to topical antifungal therapy, occasional requiring oral treatment such as griseofulvin [71,72]. Evidence from trials comparing corticosteroids and placebo trials did not show a significant difference in fungal infections, though longer corticosteroid exposure (32 weeks compared to 20 weeks) in the TENLEP clinical trial demonstrated a trend toward higher risk (RR 1.35, 98% CI 0.99 -1.84; p = 0.058) [53].

Rare opportunistic fungi such as chromoblastomycosis and phaeohyphomycosis were also documented, often occurring in agricultural workers who had prolonged high-dose corticosteroids; with a mean duration of 11 months [97,98]. There were no reports of Pneumocystis jirovecii pneumonia.

Bacterial infection

Bacterial infections, mainly identified in case reports and case series, made up 20.7% of all case reports (S5 Table).

Tuberculosis

Tuberculosis was a significant complication, responsible for almost 10% of infections in case reports, 7.9% in prospective cohorts and nearly a quarter of reported fatalities (Table 4). Cases typically occurred in individuals on high-dose or prolonged corticosteroid therapy. The onset varied from 2 months to over a year after corticosteroid initiation [72].

Other bacterial infections

Other severe bacterial infections reported in RCTs included osteomyelitis and infective endophthalmitis [72]. Four cases of nocardiosis were reported in patients who received prolonged courses of corticosteroids, including two cases caused by Nocardia farcinica and one by Nocardia nova [99–102]. One patient who was corticosteroid naïve developed Staphylococcus aureus bacteraemia in the context of newly diagnosed human immunodeficiency virus infection and initiation of antiretroviral therapy [103].

Strongyloidiasis

Infections reported to be due to Strongyloides stercoralis were severe and represented 87.5% of parasitic infections in case reports and caused two deaths (S5 Table). All reports of strongyloidiasis were in corticosteroid experienced individuals (treatment duration 5 months to more than 2 years). One case report of Strongyloides stercoralis hyperinfection syndrome occurred five years after corticosteroid initiation despite albendazole prophylaxis [104]. No parasitic infections were reported across the RCTs; however, only 21.1% of RCTs specified the use of prophylactic anti-helminthic agents, most frequently albendazole.

Gastrointestinal adverse effects

Gastritis.

Gastritis was the third most reported AE, affecting 12.6% of individuals, although definitions varied across studies. In T1R, 22.4% of participants developed gastritis. TRIPOD 1 found a 50% increased risk of gastritis with prednisolone 20mg daily over 12 weeks versus placebo (RR 1.50, 95% CI 1.10-1.32; p = 0.0124). Although the TENLEP subclinical trial showed no difference between corticosteroid and placebo groups, Lambert et al. found higher-dose prednisolone (60 mg tapered over 20 weeks) was associated with increased risk of gastritis compared to lower-dose regimens (RR 7.37, 95% CI 2.43-22.33; p < 0.001) [16]. Among participants with T2R, 20.7% of all participants developed gastritis. An RCT involving participants with ENL found that there was significant increase in risk of gastric pain, with an almost ten times higher risk in prednisolone monotherapy compared to ciclosporin with low-dose prednisolone (RR = 9.79, 95% CI 1.43-66.90; p < 0.001) [105]. Four prospective cohort studies, with follow-up duration of 6 months-5 years, reported gastritis in 2.4-8% of individuals; most cases were managed with “antacids” or oral ranitidine. Two retrospective cohort studies conducted in Indonesia and Brazil found rates of 5.6% and 10.9% respectively [86,87] (S4 Table).

Peptic ulceration.

Peptic ulceration was less frequent than gastritis. In RCTs for T1R, peptic ulceration occurred to up to 2.44% of participants receiving prednisolone 40 mg/day over 20 weeks. One fatal case of perforated peptic ulcer was reported in a participant with ENL who received at least 40mg/day of prednisolone over 16 weeks in an RCT [66]. A case report described another perforated duodenal ulcer requiring surgical intervention in a prolonged corticosteroid user [106]. Observational cohort studies reported a perforated ulcer after two weeks of corticosteroid therapy and two cases of gastric ulcers reported between one and two years after corticosteroid initiation [85].

Gastrointestinal bleeding.

Four cases of gastrointestinal bleeding were reported in RCTs, one of which was fatal [66,72](Table 4).

Ophthalmological adverse effects

Cataract.

A total of 2.3% of all individuals developed cataracts, of whom 79.6% were corticosteroid experienced. Cataract was more frequently documented in case reports and series compared to observational studies or RCTs, reflecting their progressive nature and association with long-term corticosteroid use.

Two RCTs each reported a single case of cataract, but the individuals’ characteristics were not described [55,63]. A total of 5.3% of participants among prospective cohort studies developed cataracts, observed solely in individuals with more than 12 months of corticosteroid exposure [71,72,76]. Affected individuals reported visual clouding and light sensitivity which often affected daily activities [71].

Cataracts were reported in 1-3.1% of individuals in retrospective cohort studies from Brazil, Ethiopia and Indonesia involving 358 patients, of whom 57.5% had ENL [24,85,86]. In a retrospective cohort study in Indonesia, all cases occurred in participants who had received more than 12 weeks of corticosteroid therapy [85]. Methods for cataract assessment were not clearly described; however, as data was extracted from pre-existing medical records, diagnoses were likely based on documented symptomatic presentation. A case series reported mean corticosteroid exposure from 11 months to 2.5 years [80]. Posterior subcapsular cataracts were the most common type of cataract reported and several individuals required surgery [99]. The youngest reported individual with a cataract was 27 years old on self-medicated oral corticosteroid therapy [107].

Glaucoma.

Glaucoma was found in 0.2% of all individuals. Corticosteroid-induced glaucoma was infrequent, with eight cases reported. The onset of glaucoma ranged from 32 weeks to 3 years after corticosteroid initiation [54,85]. Mishra et al. described concurrent scleromalacia perforans and glaucoma, highlighting the need for caution to prevent severe complications such as ocular perforation [80].

Cardiovascular adverse effects

Hypertension was reported in 1.6% of patients, while heart failure was not frequently reported. There were few data on the long-term morbidity and mortality of these adverse effects in individuals with leprosy on prolonged corticosteroid therapy.

Five RCTs of T1R/NFI and three of ENL reported 0.9-10% of participants developing hypertension. Participants were screened for hypertension prior to enrolment. There was no significant association between hypertension and cumulative corticosteroid dose across RCTs, though follow-up durations were short (median of 11.2 months), and only two RCTs explicitly described monitoring of blood pressure and the frequency of it [16,66]. No RCTs comparing corticosteroid with placebo reported new-onset hypertension, and no trial demonstrated a statistically significant increase in hypertensive events with higher cumulative corticosteroid doses.

One prospective cohort study, which conducted monthly blood pressure monitoring over three years, identified hypertension in 4.9% of participants receiving corticosteroids for 6–30 months [77].

Four retrospective cohorts of mostly people with ENL reported hypertension in 2-13.8% of patients, typically after more than 12 weeks of high-dose therapy, equivalent to 0.5-1mg/kg/day of prednisolone [85]. Onset ranged from 1–4 weeks to up to 3 years post-initiation [85]. One RCT reported the use of ‘anti-hypertensives’ in a single patient to manage hypertension associated with corticosteroid use [56]; however no other observational studies or RCTs provided details on the management or resolution of AEs following cessation of corticosteroid therapy.

Thrombosis

Thrombosis developed in 0.8% of individuals. Among those, 75.6% were deep vein thrombosis (DVT) and 22% had pulmonary embolism (PE), with one case of arterial thrombosis. DVT and PE were counted as separate events, even when occurring in the same patient.

Nearly all affected individuals were treated for ENL, with 93.5% receiving both thalidomide and prednisolone. Only one RCT reported a case of DVT while the remainder were described in case series and reports [63]. Two patients developed both DVT and PE on corticosteroid monotherapy: one after 10 months of prednisolone, and another after an unspecified corticosteroid duration [108,109]. No deaths were attributed to thrombosis. The thrombotic episodes were managed by discontinuing thalidomide and initiating anticoagulation.

Musculoskeletal adverse effects

Osteoporosis occurred in 0.69% of patients, predominantly in those with prolonged corticosteroid use for ENL. One RCT reported a case of vertebral collapse in an individual with ENL treated with 2mg/kg/day of prednisolone, though no further clinical details were provided [55]. In a prospective study, Sugumaran identified one individual with ENL who developed a hip fracture due to osteoporosis [72]. Affected individuals with osteoporosis had received corticosteroids for 6–12 months, and calcium supplementation was routinely given after six months; bisphosphonates were noted as effective but costly [72].

One retrospective study reported onset of osteoporosis around 30 months after corticosteroid initiation [85]. Case series and reports described osteoporosis in corticosteroid-experienced individuals with severe ENL, including a 36-year-old woman who developed thoracic vertebral collapse after intermittent prednisolone use over 10 years [110]. One case of avascular necrosis of the femoral head was reported in a person with ENL [111].

Neuropsychiatric adverse effects

Neuropsychiatric AEs, including anxiety, depression, insomnia, and corticosteroid-induced psychosis occurred in 0.6% of individuals. Insomnia developed within 9 weeks of corticosteroid initiation in a retrospective review, and corticosteroid-induced psychosis was reported 4.5 years after starting therapy [85]. No clear link was found between neuropsychiatric risk and cumulative corticosteroid dose.

Discussion

Corticosteroids remain essential for management of T1R, NFI and ENL, but their AEs including associated mortality in people affected by leprosy are clinically significant and likely underreported. Our review offers a comprehensive synthesis of corticosteroid-related AEs in the management of leprosy. Metabolic complications and infection were the most frequently reported corticosteroid-related AEs, while insidious conditions such as osteoporosis and cataract were less frequent. The findings of this review align with broader corticosteroid AEs reported in other conditions, where infection, metabolic and gastrointestinal complications are well-recognised [31,38]. In contrast, hypertension and cardiovascular events were reported less frequently in individuals with leprosy, although this may reflect limited monitoring or reporting of these AEs.

Tuberculosis emerged as the leading corticosteroid-associated cause of mortality, underscoring the need to exclude active tuberculosis prior to corticosteroid initiation and be vigilant for the reactivation of latent disease [27]. Interestingly no reports of Pneumocystis jirovecii pneumonia were identified in this review despite the increased risk of this infection in individuals treated with long-term corticosteroid in other conditions [112]. Prophylaxis for Pneumocystis jirovecii is recommended in rheumatological conditions. Recently, Ramírez-Perea and colleagues hypothesized that the dapsone component of MDT might afford individuals with leprosy some protection. They recognized that the duration of leprosy reactions often exceeds that of MDT and suggested prophylaxis should be considered in individuals with leprosy who are not taking dapsone. There is no evidence to support this approach at present [113]. Immunocompromised individuals are at greater risk of varicella zoster virus (VZV) and reactivation of hepatitis B virus, warranting assessment of immunity prior to starting corticosteroids [113–115].

Deaths associated with Strongyloides hyperinfection syndrome illustrate the importance of effective prophylaxis for this infestation on starting corticosteroid therapy in individuals at high risk of chronic strongyloidiasis [88,89]. Diagnosis can be challenging as Strongyloides stercoralis infection can remain asymptomatic for years and peripheral eosinophilia may be absent in 20–30% of infected individuals [116,117]. A study from Nepal of 145 individuals with leprosy identified 18% with S. stercoralis DNA in stool, whereas only two individuals had microscopy evidence of a soil-transmitted helminth infection [118]. Corticosteroids and other immunosuppressive drugs may further suppress peripheral eosinophilia and delay detection [119]. The WHO guidelines on preventative chemotherapy for public health control of strongyloidiasis and the National Leprosy Eradication Programme in India both have clear recommendations for empirical treatment before corticosteroid initiation to prevent disseminated strongyloidiasis [120,121].

HPA axis suppression is difficult to diagnose due to varied presentation. Though rare, the individual reported in the retrospective cohort study of Siagian et al. who suffered from adrenal suppression and growth retardation highlights potential long-term harms [85]. The UK Society for Endocrinology recommends that individuals treated with prednisolone 5mg per day or equivalent for more than 4 weeks should be given a corticosteroid emergency card to warn of adrenal crisis [122]. Advice about “sick day rules” should be provided to prevent adrenal crisis, where an increase in the regular corticosteroid dosage is recommended to reduce the risk of adrenal crisis during intercurrent illness [122]. Adrenal crisis should be suspected in an acutely deteriorating individual on corticosteroids, and may require immediate treatment with intravenous hydrocortisone [123].

Our systematic review has limitations. The review process was conducted primarily by an independent reviewer which may have introduced selection bias. The heterogeneity in study designs, interventions, definitions of AEs, and study quality limited the ability to make direct comparisons between studies and precluded meta-analysis. A further limitation is that we were obliged to rely on the information provided in the authors’ accounts of included studies to ascertain the status of corticosteroid exposure and causes of death. The narrative nature of this review means there is a risk of confounding when exploring the temporal association between corticosteroid exposure and adverse effects. Potential publication bias may have led to the underrepresentation of AEs that are underreported. Most studies were conducted in referral settings, where loss to follow-up may lead to underreporting of the frequency of AEs.

Monitoring for AEs is essential for all individuals with leprosy on corticosteroids. Fig 2 provides a framework for consideration when designing context-appropriate monitoring guidelines to identify and reduce the burden of AEs in adults with leprosy in endemic areas [124–126]. Children may need additional monitoring as approximately one-fifth of children exposed to long term oral corticosteroids may experience growth retardation [85,114].

thumbnail
Download:
Fig 2. XXX.

https://doi.org/10.1371/journal.pntd.0014152.g002

Before corticosteroid initiation, consideration should be given to the availability of corticosteroid-sparing agents, such as thalidomide for ENL [27]. Although the United States National Hansen’s Disease Program (NHDP) recommends methotrexate as an adjunct to corticosteroids for T1R, there remains limited published evidence to support this [127].

Once corticosteroid therapy is indicated, a pre-treatment assessment should screen individuals for metabolic comorbidities, blood-borne viruses (hepatitis B and C, and HIV) and tuberculosis [128]. Where available, a chest radiograph may be used in addition to symptom screening for active tuberculosis in high-risk groups [129]. Routine vaccination status should be assessed and any additional vaccinations considered [130].

Patients should receive appropriate counselling on the risks of corticosteroid treatment before initiation, as emphasized in Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase of the Brazilian Ministry of Health [131]. There were several reports of severe adverse outcomes associated with the unsupervised self-administration of corticosteroids found in this review and this should be discouraged [80,106]. Information on AE symptoms and the risks of self-medication without supervision should be provided in accessible formats that account for illiteracy [8].

Prior to initiation of corticosteroids prevention therapies for strongyloidiasis, peptic ulceration, osteoporosis and venous thromboembolism should be considered.

Empirical treatment for strongyloidiasis is essential, with single-dose ivermectin recommended by WHO and The World Gastroenterology Organisation [120,132]. A Cochrane systematic review and meta-analysis found higher cure rates for ivermectin compared to albendazole, with no significant difference in AE rates between the two drugs [133].

Prophylaxis for gastrointestinal disorders was inconsistently reported across studies. The WHO Technical Guidance for reactions and the Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase both acknowledge AEs of dyspepsia and gastrointestinal ulceration from corticosteroid use but neither addressed the role of proton pump inhibitors (PPI). The National Institute for Health and Care Excellence (NICE) and EULAR advise considering PPIs for individuals at high risk of gastrointestinal bleeding or dyspepsia [124,134]. In contrast, the Asociación Mexicana de Gastroenterología (AMG) advises against chronic PPI prescription in patients receiving corticosteroids alone, recommending it only when non-steroidal anti-inflammatory drugs or antiplatelet agents are also prescribed [135].

Osteoporosis was often only detected at advanced stages when fractures had occurred [55,72]. Preventive measures with calcium and vitamin D supplementation should be prescribed, and bisphosphonates are recommended for individuals at moderate to high risk of fracture; based on bone mineral density and Fracture Risk Assessment Tool (FRAX) score [33,136]. This is in accordance with Indian Association of Dermatologists, Venereologists and Leprologists (IADVL), American College of Rheumatology, and NICE guidelines [124,136,137].

Thromboprophylaxis should be considered when thalidomide is co-prescribed with corticosteroids as there is an increased risk of thrombosis [138]. The European Myeloma Network guidelines and The Leprosy Mission Trust India (TLMTI) guidance recommend low-dose aspirin for individuals at low risk [125,139]. For patients with multiple risk factors, the European Myeloma Network advises low molecular weight heparin or warfarin [139].

Patients should be asked about symptoms of adverse effects and regularly monitored for hypertension, glucocorticoid-induced diabetes mellitus and dyslipidaemia [140,141]. TLMTI guidance recommends monitoring of blood pressure at every outpatient visit, and glucose after one month and three monthly thereafter [125]. The IADVL manual recommends blood sugar monitoring 24–48 hours after initiation of corticosteroids, and no further monitoring if levels are normal [137].

The incidence of cataract was largely associated with prolonged exposure [142,143], and since individuals with leprosy are already predisposed to ocular complications, frequent monitoring and early detection of corticosteroid-associated cataract is essential to prevent G2D [143]. Ophthalmic monitoring should be standardized to detect early cataract and glaucoma, as the young onset of cataracts reported in case reports highlight the danger of unsupervised high-dose corticosteroids [80,125]. Both TLMTI and IADVL suggest ophthalmological evaluation, with monitoring frequency ranging from every month to every 6–12 months [125,137].

Effective corticosteroid stewardship requires the lowest effective dose for the shortest possible duration. Corticosteroid stewardship is critical but may be constrained by limited resources in many leprosy endemic settings [144]. Effective monitoring imposes financial and logistical burdens on the health system and on patients. The direct and indirect costs to affected individuals of attendance at leprosy referral centres may make visits for regular monitoring challenging [145]. Counselling and peer-support interventions may have a role in enhancing corticosteroid stewardship [10,146]. WHO-aligned pharmacovigilance and surveillance strategies to support corticosteroid AE reporting and monitoring could help reduce avoidable morbidity and mortality [147].

Reducing AEs associated with corticosteroids in people affected by leprosy is a priority. This requires patient education, thorough clinical assessment prior to initiation, robust monitoring, effective morbidity prevention and access to effective alternative treatments for leprosy reactions. The WHO has recognised the need for improved pharmacovigilance for MDT; this also needs to be strengthened for the adverse effects of corticosteroids and other immunomodulatory treatments in the management of leprosy reactions [27].

Supporting information

S1 File. PRISMA 2020 checklist from Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71, licensed under CC BY 4.0.

https://doi.org/10.1371/journal.pntd.0014152.s001

(PDF)

S1 Text. Search strategy.

https://doi.org/10.1371/journal.pntd.0014152.s002

(PDF)

S1 Table. Risk of bias assessment for randomised controlled trials.

https://doi.org/10.1371/journal.pntd.0014152.s003

(PDF)

S2 Table. Risk of bias assessment for observational studies.

https://doi.org/10.1371/journal.pntd.0014152.s004

(PDF)

S3 Table. Table of summary of prospective cohort studies.

https://doi.org/10.1371/journal.pntd.0014152.s005

(PDF)

S4 Table. Table of summary of retrospective cohort studies.

https://doi.org/10.1371/journal.pntd.0014152.s006

(PDF)

S5 Table. Proportion of case reports and case series recording rarer adverse events.

https://doi.org/10.1371/journal.pntd.0014152.s007

(PDF)

Acknowledgments

All authors have reviewed the manuscript and take full responsibility for its original content. The use of artificial intelligence was limited to grammar check during manuscript preparation.

References

  1. 1. Le PH, Philippeaux S, Mccollins T, Besong C, Kellar A, Klapper VG, et al. Pathogenesis, clinical considerations, and treatments: a narrative review on leprosy. Cureus. 2023;15(12):e49954. pmid:38179342
  2. 2. Grijsen ML, Nguyen TH, Pinheiro RO, Singh P, Lambert SM, Walker SL. Leprosy. Nature Rev Disease Prim. 2024;10(1):90.
  3. 3. World Health Organization. Global leprosy (Hansen disease) update, 2024: beyond zero cases – what elimination of leprosy really means. Weekly Epidemiol Rec. 2024;100(33):365–84.
  4. 4. Fischer M. Leprosy - an overview of clinical features, diagnosis, and treatment. J Dtsch Dermatol Ges. 2017;15(8):801–27. pmid:28763601
  5. 5. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73. pmid:5950347
  6. 6. Penna GO, Bührer-Sékula S, Kerr LRS, Stefani MM de A, Rodrigues LC, de Araújo MG, et al. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS Negl Trop Dis. 2017;11(7):e0005725. pmid:28704363
  7. 7. de Paula HL, de Souza CDF, Silva SR, Martins-Filho PRS, Barreto JG, Gurgel RQ, et al. Risk factors for physical disability in patients with leprosy: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(10):1120–8. pmid:31389998
  8. 8. van Brakel WH, Sihombing B, Djarir H, Beise K, Kusumawardhani L, Yulihane R, et al. Disability in people affected by leprosy: the role of impairment, activity, social participation, stigma and discrimination. Glob Health Action. 2012;5:10.3402/gha.v5i0.18394. pmid:22826694
  9. 9. Serrano-Coll H, Wan EL, Restrepo-Rivera L, Cardona-Castro N. Leprosy reactions: Unraveling immunological mechanisms underlying tissue damage in leprosy patients. Pathog Dis. 2024;82:ftae013. pmid:38806255
  10. 10. Putri AI, de Sabbata K, Agusni RI, Alinda MD, Darlong J, de Barros B, et al. Understanding leprosy reactions and the impact on the lives of people affected: an exploration in two leprosy endemic countries. PLoS Negl Trop Dis. 2022;16(6):e0010476. pmid:35696438
  11. 11. Froes LAR J, Sotto MN, Trindade MAB. Leprosy: clinical and immunopathological characteristics. An Bras Dermatol. 2022;97(3):338–47. pmid:35379512
  12. 12. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis. 2004;72(2):125–33. pmid:15301592
  13. 13. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005;76(1):14–34. pmid:15881033
  14. 14. Nery JA da C, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira S de SC, Sales AM. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol. 2013;88(5):787–92. pmid:24173185
  15. 15. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev. 2003;74(4):311–8. pmid:14750576
  16. 16. Lambert SM, Alembo DT, Nigusse SD, Yamuah LK, Walker SL, Lockwood DNJ. A randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction, in Ethiopia. PLoS Negl Trop Dis. 2016;10(4):e0004502. pmid:27046330
  17. 17. Upputuri B, Pallapati MS, Tarwater P, Srikantam A. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: a five-year retrospective analysis from a leprosy referral centre in India. PLoS Negl Trop Dis. 2020;14(10):e0008678. pmid:33035210
  18. 18. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006;74(5):868–79. pmid:16687695
  19. 19. Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, et al. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. PLoS Negl Trop Dis. 2015;9(9):e0004065. pmid:26351858
  20. 20. Darlong J, Govindharaj P, Charles DE, Menzies A, Mani S. Experiences with thalidomide for erythema nodosum leprosum– a retrospective study. Lepr Rev. 2016;87(2):211–20. pmid:30212168
  21. 21. Nabarro LEB, Aggarwal D, Armstrong M, Lockwood DNJ. The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London. Leprosy. 2016;87(2):221–31.
  22. 22. Voorend CGN, Post EB. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis. 2013;7(10):e2440. pmid:24098819
  23. 23. Van Veen NHJ, Lockwood DNJ, Van Brakel WH, Ramirez J Jr, Richardus JH. Interventions for erythema nodosum leprosum: a cochrane review. Lepr Rev. 2009;80(4):355–72. pmid:20306635
  24. 24. Walker SL, Lebas E, Doni SN, Lockwood DNJ, Lambert SM. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. PLoS Negl Trop Dis. 2014;8(3):e2690. pmid:24625394
  25. 25. Lowe JA. A.C.T.H. and cortisone in treatment of complications of leprosy. British Medical Journal. 1952;2(4787):746–9.
  26. 26. Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr Rev. 2000;71 Suppl:S111-4. pmid:11201865
  27. 27. World Health Organization. Leprosy/Hansen Disease: Management of reactions and prevention of disabilities. New Delhi: World Health Organization; 2020. https://iris.who.int/bitstream/handle/10665/332022/9789290227595-eng.pdf?sequence=1
    • 28. Walker SL, Waters MFR, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev. 2007;78(3):197–215. pmid:18035771
    • 29. Ruth Butlin C, Darlong J, Mukhier M. Access to thalidomide. Leprosy. 2023;94(3):186–92.
    • 30. Chastain DB, Spradlin M, Ahmad H, Henao-Martínez AF. Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults. Clin Infect Dis. 2024;78(4):e37–56. pmid:37669916
    • 31. Canonica GW, Porsbjerg C, Price DB, Wechsler ME, Heaney LG, Hanania NA, et al. Burden of oral corticosteroid use in severe asthma: challenges and opportunities. Allergy. 2025;80(8):2113–27. pmid:40548588
    • 32. Hmamouchi I, Paruk F, Tabra S, Maatallah K, Bouziane A, Abouqal R, et al. Prevalence of glucocorticoid-induced osteoporosis among rheumatology patients in Africa: a systematic review and meta-analysis. Arch Osteoporos. 2023;18(1):59. pmid:37129714
    • 33. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10(10):CD001347. pmid:27706804
    • 34. Golubic R, Mumbole H, Ismail MH, Choo A, Baker O, Atha K, et al. Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Diabet Med. 2025;42(3):e15475. pmid:39642210
    • 35. Deng H-W, Mei W-Y, Xu Q, Zhai Y-S, Lin X-X, Li J, et al. The role of glucocorticoids in increasing cardiovascular risk. Front Cardiovasc Med. 2023;10:1187100. pmid:37476574
    • 36. Beuschlein F, Else T, Bancos I, Hahner S, Hamidi O, van Hulsteijn L, et al. European society of endocrinology and endocrine society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024;109(7):1657–83.
    • 37. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57(4):604–9. pmid:17582650
    • 38. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145–53. pmid:22271756
    • 39. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87. pmid:12378366
    • 40. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide M-V, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. pmid:19604357
    • 41. Canada’s Drug Agency. Canada’s drug agency search filters database. 2025. Accessed 2025 July 28. https://searchfilters.cda-amc.ca/link/2
      • 42. World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy Geneva, Switzerland: World Health Organization; 2018. https://iris.who.int/bitstream/handle/10665/274127/9789290226383-eng.pdf
        • 43. Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491–509. pmid:34937122
        • 44. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. pmid:31462531
        • 45. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. pmid:20652370
        • 46. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–33. pmid:33038125
        • 47. Deeks JJHJ, Altman DG, McKenzie JE, Veroniki AA. Cochrane handbook for systematic reviews of interventions. 2024.
          • 48. Julian PT, Higgins TL, Deeks JJ. Cochrane handbook for systematic reviews of interventions. 2024.
            • 49. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the “TRIPOD” trials. Lepr Rev. 2003;74(4):319–27. pmid:14750577
            • 50. Post E, Wagenaar I, Brandsma W, Bowers B, Alam K, Shetty V, et al. Prednisolone adverse events in the treatment and prevention of leprosy neuropathy in two large double blind randomized clinical trials. Leprosy Rev. 2021;92(3):236–46.
            • 51. Smith WCS, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ. 2004;328(7454):1459. pmid:15159285
            • 52. Van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, Richardus JH, et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev. 2003;74(4):300–10. pmid:14750575
            • 53. Wagenaar I, Post E, Brandsma W, Bowers B, Alam K, Shetty V, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: a randomized controlled trial. PLoS Negl Trop Dis. 2017;11(10):e0005952. pmid:28976976
            • 54. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M, Mahat K, et al. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis. 2011;5(4):e1041. pmid:21532737
            • 55. Garbino JA, Virmond M da CL, Ura S, Salgado MH, Naafs B. A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and type 2 leprosy reactions. Arq Neuropsiquiatr. 2008;66(4):861–7. pmid:19099126
            • 56. Marlowe SNS, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DNJ. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg. 2004;98(10):602–9. pmid:15289097
            • 57. Lockwood DNJ, Darlong J, Govindharaj P, Kurian R, Sundarrao P, John AS. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. PLoS Negl Trop Dis. 2017;11(3):e0005348. pmid:28358815
            • 58. Girdhar A, Chakma JK, Girdhar BK. Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study. Indian J Lepr. 2002;74(3):233–6. pmid:12708702
            • 59. Sakhare P, Wagh R, Gaikwad R, Waghmare PL, Rao SP. Evaluation of methotrexate and sodium stibogluconate in the patients of type two lepra reactions. Inter J Pharm Clin Res. 2024;16(1):448–54.
            • 60. Karat AB, Jeevaratnam A, Karat S, Rao PS. Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy. Br Med J. 1970;1(5690):198–200. pmid:4904935
            • 61. Ing TH. Indomethacin in the treatment of erythema nodosum leprosum, in comparison with prednisolone. Singapore Med J. 1969;10(1):66–70. pmid:5803564
            • 62. Karat AB, Thomas G, Rao PS. Indomethacin in the management of erythema nodosum leprosum--a double-blind controlled trial. Lepr Rev. 1969;40(3):153–8. pmid:4900710
            • 63. Kar HK, Gupta L. Comparative efficacy of four treatment regimens in Type 2 leprosy reactions (Prednisolone alone, Thalidomide alone, Prednisolone plus Thalidomide and Prednisolone plus Clofazimine). Indian J Lepr. 2016;88(1):29–38. pmid:29741823
            • 64. Kaur I, Dogra S, Narang T, De D. Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol. 2009;50(3):181–5. pmid:19659979
            • 65. Doull JA, Tolentino JG, Guinto RS, Rodriguez JN, Leano LM, Fernandez JV, et al. Clinical evaluation studies in lepromatous leprosy. Sixth series: effect (on lepra reaction) of supplementing DDS with dexamethasone, methandrostenolone, or mefenamic acid. Int J Lepr Other Mycobact Dis. 1967;35(2):128–39. pmid:5338957
            • 66. Lambert SM, Nigusse SD, Alembo DT, Walker SL, Nicholls PG, Idriss MH, et al. Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: two randomised, double blind, controlled pilot studies in ethiopia. PLoS Negl Trop Dis. 2016;10(2):e0004149. pmid:26919207
            • 67. Hanumanthu V, Thakur V, Narang T, Dogra S. Comparison of the efficacy and safety of minocycline and clofazimine in chronic and recurrent erythema nodosum leprosum-A randomized clinical trial. Dermatol Ther. 2021;34(6):e15125. pmid:34490707
            • 68. Roy K, Sil A, Das NK, Bandyopadhyay D. Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study. Int J Dermatol. 2015;54(11):1325–32. pmid:26094723
            • 69. Martinus D, Menaldi SL, Rihatmadja R. Comparison between oral pentoxifylline corticosteroid and oral corticosteroid alone for severe erythema nodosum leprosum: a randomized, double-blind controlled trial. In: Journal of the Dermatology Nurses’ Association Conference, Milan, Italy, 2020.
              • 70. Kundu SK, Hazra SK, Ghosh S, Chaudhuri S. Corticosteroids and lepromin sensitivity. Lepr India. 1982;54(3):489–98.
              • 71. Sugumaran DS. Steroid therapy for paralytic deformities in leprosy. Int J Lepr Other Mycobact Dis. 1997;65(3):337–44. pmid:9401486
              • 72. Sugumaran DS. Leprosy reactions--complications of steroid therapy. Int J Lepr Other Mycobact Dis. 1998;66(1):10–5. pmid:9614834
              • 73. Papang R, John AS, Abraham S, Rao PSSS. A study of steroid-induced diabetes mellitus in leprosy. Indian J Lepr. 2009;81(3):125–9. pmid:20509340
              • 74. Srinivasan H, Rao KS, Shanmugam N. Steroid therapy in recent “quiet nerve paralysis” in leprosy. Report of a study of twenty-five patients. Lepr India. 1982;54(3):412–9. pmid:7176532
              • 75. Thirugnanam T, Rajan MA. Borderline reactions treated with clofazimine and corticosteroids. Indian J Lepr. 1985;57(1):164–71. pmid:3839816
              • 76. Saunderson P, Gebre S, Desta K, Byass P. The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics. Leprosy Review. 2000;71(3):273–84.
              • 77. Singla P, Joshi R, Shah BJ. Thalidomide in severe erythema nodosum leprosum (Enl)-our experience in chronic, recurrent and steroid-dependant cases. Indian J Leprosy. 2021;93(2):115–28.
              • 78. Hossain D. Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. Lepr Rev. 2013;84(1):105–12. pmid:23741889
              • 79. Negera E, Tilahun M, Bobosha K, Lambert SM, Walker SL, Spencer JS, et al. The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions. PLoS Negl Trop Dis. 2018;12(12):e0007035. pmid:30592714
              • 80. Mishra S, Madhual S, Panda M. Managing a case of steroid dependant erythema necroticans in a severely immune-compromised patient: Case report. Indian J Leprosy. 2024;96:243–7.
              • 81. Bandeira SS, Pires CA, Quaresma JAS. Leprosy reactions in childhood: a prospective cohort study in the brazilian amazon. Infect Drug Resist. 2019;12:3249–57. pmid:31802916
              • 82. Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganapati R. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT. Lepr Rev. 2010;81(1):41–58. pmid:20496569
              • 83. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Lepr Rev. 1985;56(2):127–34. pmid:4021699
              • 84. P K Mishra SR, Samal R, Behera B. Thalidomide and steroid in the management of erythema nodosum leprosum. Indian J Pharmacol. 2022;54(3):177–82. pmid:35848688
              • 85. Siagian JN, Purwantyastuti I, Menaldi SL. Analysis of therapeutic effectiveness and adverse effects of long-term corticosteroids among leprosy patients with reactions: a retrospective cohort study. SAGE Open Med. 2022;10:20503121221089448. pmid:35465634
              • 86. Neves D, Sales AM, Nery JAC, Illarramendi X, de Souza RV, Rosa TFL, et al. Retrospective study of the morbidity associated with erythema nodosum leprosum in Brazilian leprosy patients. Leprosy Review. 2019;90(1):68–77.
              • 87. Listiyawati I, Sawitri S, Agusni I, Prakoeswa C. Oral corticosteroid therapy in leprosy’s new patients with type 2 reaction. Period Dermatol Venereol. 2015;27(1).
              • 88. Leang B, Lynen L, Tootill R, Griffiths S, Monchy D. Death caused by strongyloides hyperinfection in a leprosy patient on treatment for a type II leprosy reaction. Lepr Rev. 2004;75(4):398–403. pmid:15682976
              • 89. Mutreja D, Sivasami K, Tewari V, Nandi B, Nair GL, Patil SD. A 36-year-old man with vomiting, pain abdomen, significant weight loss, hyponatremia, and hypoglycemia. Indian J Pathol Microbiol. 2015;58(4):500–5. pmid:26549076
              • 90. Davis SV, Shenoi SD, Balachandran C, Pai SB. A fatal case of erythema necroticans. Indian J Lepr. 2002;74(2):145–9. pmid:12708733
              • 91. Pai S, Munshi R, Nayak C. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus. Indian J Pharmacol. 2017;49(5):396–8. pmid:29515281
              • 92. Zhu J, Yang D, Shi C, Jing Z. Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum. Am J Trop Med Hyg. 2017;96(6):1362–4. pmid:28719256
              • 93. Edward VK. Diabetic ketoacidosis following steroid therapy in a rural leprosy hospital. Int J Lepr Other Mycobact Dis. 1995;63(2):289–91. pmid:7602224
              • 94. Morel R, Maddumabandara K, Amarasinghe N, Amarangani S, Amarasinghe A, Gunathilaka M, et al. Strongyloidiasis infection in a borderline lepromatous leprosy patient with adrenocorticoid insufficiency undergoing corticosteroid treatment: a case report. J Med Case Rep. 2022;16(1):458. pmid:36482424
              • 95. Monteiro R, Bhat I, Pratibha JP. Hypothalamo-pituitary axis suppression: a risk factor for late onset bullous ENL?. Indian J Leprosy. 2016;88(4):237–40.
              • 96. Darlong J. Strongyloides hyper infection in a steroid dependent leprosy patient. Lepr Rev. 2016;87(4):536–42. pmid:30226358
              • 97. Teixeira MMR, Assunção CB, Lyon S, Gomes RR, Junior HBM, Rocha-Silva F, et al. A case of subcutaneous phaeohyphomycosis associated with leprosy. Infect Disord Drug Targets. 2017;17(3):223–6. pmid:28558644
              • 98. Yadav SK, Chandana BK, Panwar H, Chaurasia JK, Jayashankar E, Asati D. Role of cytopathology in diagnosing phaeohyphomycosis masquerading as nerve abscess in a lepromatous leprosy patient: a case report. Int J Surg Case Rep. 2023;110:108741. pmid:37657385
              • 99. Arunthathi S, Ebenezer G, Daniel E, Sugumaran ST. Nocardia farcinica pleuritis in a lepromatous patient with severe necrotizing reaction: an unusual presentation. Int J Lepr Other Mycobact Dis. 2001;69(2):104–7. pmid:11757165
              • 100. De Nardo P, Giancola ML, Noto S, Gentilotti E, Ghirga P, Tommasi C, et al. Left thigh phlegmon caused by Nocardia farcinica identified by 16S rRNA sequencing in a patient with leprosy: a case report. BMC Infect Dis. 2013;13:162. pmid:23556433
              • 101. Dhingra M, Kaistha N, Bansal N, Solanki LS, Chander J, Thami GP, et al. Nocardia nova mycetoma over forehead in a lepromatous leprosy patient. Dermatol Online J. 2012;18(7):3. pmid:22863625
              • 102. Pretty M, Bifi J, Radhakrishnan K, Hashba H. Systemic nocardiosis in a lepromatous leprosy patient with type 2 reaction. Int J Dermatol. 2018;57(5):620–2. pmid:29520868
              • 103. Talhari C, Ferreira LC de L, Araújo JR, Talhari AC, Talhari S. Immune reconstitution inflammatory syndrome or upgrading type 1 reaction? Report of two AIDS patients presenting a shifting from borderline lepromatous leprosy to borderline tuberculoid leprosy. Lepr Rev. 2008;79(4):429–35. pmid:19274990
              • 104. De Souza JN, Machado PRL, Teixeira MCA, Soares NM. Recurrence of strongyloides stercoralis infection in a patient with Hansen’s disease: a case report. Lepr Rev. 2014;85(1):58–62. pmid:24974444
              • 105. de Barros B, Lambert SM, Shah M, Pai VV, Darlong J, Rozario BJ, et al. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. BMJ Open. 2020;10(11):e037700. pmid:33203627
              • 106. Dawe S, Lockwood DNJ, Creamer D. A case of post-partum borderline tuberculoid leprosy complicated by a median nerve abscess, peptic ulceration and rifampicin-induced haemolytic renal failure. Lepr Rev. 2004;75(2):181–7. pmid:15282971
              • 107. Daniel E, Alexander R, Chacko S. Ocular leprosy: do steroids complicate matters?. Int J Lepr Other Mycobact Dis. 1995;63(1):115–7. pmid:7730712
              • 108. Thangaraju P, Giri VC, Aravindan U, Sajitha V, Showkath Ali MK. Ileofemoral Deep Vein Thrombosis (DVT) in steroid treated lepra type 2 reaction patient. Indian J Lepr. 2015;87(3):165–8. pmid:26999989
              • 109. Vernal S, Brochado MJF, Bueno-Filho R, Louzada-Junior P, Roselino AM. Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles. Rev Soc Bras Med Trop. 2018;51(1):99–104. pmid:29513853
              • 110. Lombardi V, Di Giovanni T, Zizza F. Acute collapse of thoracic vertebral bodies after long-term steroid treatment in leprosy. Surg Neurol. 1982;17(4):293–4. pmid:7079956
              • 111. Nguyen V a n U. The danger of steroid therapy in leprosy. International Journal of Leprosy. 1973;41(4):708.
              • 112. Miyake K, Senoo S, Shiiba R, Itano J, Kimura G, Kawahara T, et al. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: a multicenter, retrospective cohort study. PLoS One. 2024;19(2):e0292507. pmid:38330061
              • 113. Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742–53. pmid:36328476
              • 114. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016;101(4):365–70. pmid:26768830
              • 115. Putri AK, Widjajanto PH, Arguni E. Factors associated with mortality in immunocompromised children with varicella. BMC Pediatr. 2025;25(1):671. pmid:40887615
              • 116. Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J. Strongyloidiasis--an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8(8):e3018.
              • 117. Buonfrate D, Fittipaldo A, Vlieghe E, Bottieau E. Clinical and laboratory features of Strongyloides stercoralis infection at diagnosis and after treatment: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(11):1621–8. pmid:34325063
              • 118. Hagge DA, Parajuli P, Kunwar CB, Rana DRSJB, Thapa R, Neupane KD, et al. Opening a can of worms: leprosy reactions and complicit soil-transmitted helminths. EBioMedicine. 2017;23:119–24. pmid:28882756
              • 119. Fardet L, Généreau T, Poirot J-L, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54(1):18–27. pmid:16533536
              • 120. World Health Organization. WHO guideline on preventative chemotherapy for public health control of strongyloidiasis. Geneva: World Health Organization; 2024. https://iris.who.int/server/api/core/bitstreams/cb24da76-b254-4a3f-ae03-b4cb97cd579e/content
                • 121. National Leprosy Eradication Programme. National strategic plan and roadmap for leprosy 2023-2027. Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; 2023. https://nlrindia.org/wp-content/uploads/2024/03/NSP-Roadmap-for-Leprosy-2023-2027.pdf
                  • 122. Society for Endocrinology. Adrenal insufficiency and adrenal crisis-who is at risk and how should they be managed safely. 2021. Accessed 2025 August 20. https://www.endocrinology.org/media/4091/spssfe_supporting_sec_-final_10032021-1.pdf
                    • 123. Arlt W, Society for Endocrinology Clinical Committee. Society for endocrinology endocrine emergency guidance: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016;5(5):G1–3. pmid:27935813
                    • 124. National Institute for Health and Care Excellence. Scenario: corticosteroids. 2025. Accessed 2025 September 14. https://cks.nice.org.uk/topics/corticosteroids-oral/management/corticosteroids/#monitoring
                      • 125. The Leprosy Mission Trust India. Leprosy Care. New Delhi, India; 2020.
                        • 126. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. pmid:23947590
                        • 127. Health Resources and Services Administration. NHDP guide to the management of Hansen’s disease. Health Resources & Services Administration; 2025. https://www.hrsa.gov/hansens-disease
                          • 128. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization. 2023; https://www.who.int/publications/i/item/9789240083851
                            • 129. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021.
                              • 130. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. pmid:31413005
                              • 131. Saúde MSSV. Protocolo clínico e diretrizes terapêuticas da hanseníase Brasil. Brasília: Ministério da Saúde. 2022. https://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_terapeuticas_hanseniase.pdf
                                • 132. Management of strongyloidiasis. World Gastroenterology Organisation; 2018. https://researchonline.lshtm.ac.uk/id/eprint/4658758/1/Farthing-etal-2020_World%20Gastroenterology_Organisation_Global_Guidelines_Management_of_Strongyloidiasis.pdf
                                  • 133. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016;2016(1):CD007745. pmid:26778150
                                  • 134. Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7. pmid:17660219
                                  • 135. Valdovinos-García LR, Villar-Chávez AS, Huerta-Iga FM, Amieva-Balmori M, Arenas-Martínez JS, Bernal-Reyes R, et al. Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG. Rev Gastroenterol Mex (Engl Ed). 2025;90(1):111–30. pmid:40307154
                                  • 136. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405–19. pmid:37884467
                                  • 137. Indian Association of Dermatologists V, Leprologists IADVL. User’s manual of systemic and topical steroids. CBS Publishers and Distributors Pvt Ltd; 2020.
                                    • 138. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431–6. pmid:16365178
                                    • 139. Gerotziafas G, Fotiou D, Nijhof I, Ay C, Lecumberri R, Laroca A, et al. Prevention and treatment of venous thromboembolism in patients with multiple myeloma: clinical practice guidelines on behalf of the European Myeloma Network. Hemasphere. 2025;9(8):e70177. pmid:40880878
                                    • 140. Krishnamoorthy Y, Rajaa S, Murali S, Rehman T, Sahoo J, Kar SS. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS One. 2020;15(10):e0240971. pmid:33075086
                                    • 141. França SL, Lima SS, Vieira JRDS. Metabolic syndrome and associated factors in adults of the amazon region. PLoS One. 2016;11(12):e0167320. pmid:27936021
                                    • 142. Carlson J, McBride K, O’Connor M. Drugs associated with cataract formation represent an unmet need in cataract research. Front Med (Lausanne). 2022;9:947659. pmid:36045926
                                    • 143. Hogeweg M. Cataract: the main cause of blindness in leprosy. Lepr Rev. 2001;72(2):139–42. pmid:11495444
                                    • 144. Peng W, Zhang L, Wen F, Tang X, Zeng L, Chen J, et al. Trends and disparities in non-communicable diseases in the Western Pacific region. Lancet Reg Health West Pac. 2023;43:100938. pmid:38456093
                                    • 145. Chandler DJ, Hansen KS, Mahato B, Darlong J, John A, Lockwood DNJ. Household costs of leprosy reactions (ENL) in rural India. PLoS Negl Trop Dis. 2015;9(1):e0003431. pmid:25590638
                                    • 146. Maulana AT, Putri AI, Mengistu BS, Walker SL, Peters RMH. Development, validation and reliability of knowledge, attitudes and practice questionnaire for people affected by leprosy reactions. Glob Public Health. 2025;20(1):2501163. pmid:40356216
                                    • 147. World Health Organization. Regulation and prequalification. World Health Organization; 2025. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance